Riva Therapeutics

Executive Summary

Riva Therapeutics is a precision oncology company developing a novel class of small molecule therapeutics that exploit genomic dependencies in cancer cells, with a focus on targets beyond DNA damage repair. Founded in 2021 and headquartered in San Francisco, the company leverages deep biological insights to identify essential tumor cell processes that can be selectively inhibited, aiming to deliver potent, well-tolerated treatments. Riva's 'precision lethal' approach is designed to provide profound clinical activity while minimizing off-target toxicity, potentially offering transformative benefits to patients with genetically defined cancers. Although still in the preclinical stage, the company's unique strategy positions it to address significant unmet needs in oncology, particularly in tumors with specific genomic vulnerabilities. The company is private and has not yet disclosed its pipeline or funding details, indicating an early development phase with upcoming milestones critical for advancing its programs.

Upcoming Catalysts (preview)

• Q4 2026IND filing for lead precision lethal program70% success
• H1 2027Initiation of first-in-human Phase 1 trial60% success
• Q3 2026Publication of key preclinical data in peer-reviewed journal80% success